针对EGFR三重突变的PROTACs的合成和降解效应
Xiao-Xiao Xi1, Hong-Yi Zhao1, Minhang Xin1
1Department of Medicinal Chemistry, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, PR China.
Bioorganic & medicinal chemistry
|October 11, 2025
概括
开发了针对EGFR三重突变的新型PROTAC. 化合物EP9和EP12有效降解了这些突变,为癌症治疗中耐药性提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 皮表皮生长因子受体 (EGFR) 突变驱动癌症药物耐药性,限制EGFR氨酸激酶抑制剂 (EGFR-TKI) 的有效性.
- 解决耐药性,特别是像EGFRDel19/T790M/C797S和EGFRL858R/T790M/C797S这样的三重突变,对于改善患者的结果至关重要.
研究的目的:
- 设计和合成能够降解EGFR三重突变的新型蛋白质分解向化马体 (PROTACs).
- 评估新设计的PROTAC化合物对EGFR突变癌细胞的抗增殖活性和降解疗效.
主要方法:
- 利用第四代EGFR-TKIs和VHL-ligands与基链接器构建针对EGFR三重突变的PROTAC.
- 合成并选了12种PROTAC化合物的库 (EP1-EP12).
- 研究了EGFR降解的机制,包括三元复合体的形成,ubiquitination和 lysosomal路径的参与.
主要成果:
- 化合物EP7,EP8,EP9,EP11和EP12对EGFR突变细胞表现出强大的抗增殖作用.
- EP9和EP12显著诱导了EGFR三重突变 (EGFRDel19/T790M/C797S和EGFRL858R/T790M/C797S) 的降解.
- 这些PROTAC有效地抑制了EGFR通路信号传递,并且需要无化和溶酶体活性来降解.
结论:
- 化合物EP9和EP12被确定为EGFR三重突变的有效PROTAC降解剂.
- 这些发现为开发基于PROTAC的新型疗法提供了宝贵的见解,以克服EGFR-TKI耐药性.
- 这项研究强调了PROTAC技术在针对具有挑战性的癌症突变方面的潜力.
相关概念视频
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Enzyme-linked Receptors
85.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
85.9K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K


